Computational Drug Repositioning Using Continuous Self-controlled Case
  Series by Kuang, Zhaobin et al.
Computational Drug Repositioning Using
Continuous Self-controlled Case Series
Zhaobin Kuang1, James Thomson2, Michael Caldwell3,
Peggy Peissig4, Ron Stewart5, David Page6
UW-Madison1,6, Morgridge Institute2,5, Marshfield Clinic3,4
zkuang@wisc.edu1, page@biostat.wisc.edu6,
JThomson@morgridge.org2, RStewart@morgridgeinstitute.org5,
caldwell.michael@marshfieldclinic.org3, Peissig.Peggy@mcrf.mfldclin.edu4
ABSTRACT
Computational Drug Repositioning (CDR) is the task of
discovering potential new indications for existing drugs by
mining large-scale heterogeneous drug-related data sources.
Leveraging the patient-level temporal ordering information
between numeric physiological measurements and various
drug prescriptions provided in Electronic Health Records
(EHRs), we propose a Continuous Self-controlled Case Se-
ries (CSCCS) model for CDR. As an initial evaluation, we
look for drugs that can control Fasting Blood Glucose (FBG)
level in our experiments. Applying CSCCS to the Marshfield
Clinic EHR, well-known drugs that are indicated for control-
ling blood glucose level are rediscovered. Furthermore, some
drugs with recent literature support for the potential effect
of blood glucose level control are also identified.
CCS Concepts
•Mathematics of computing → Regression analysis;
•Applied computing → Health care information sys-
tems; Health informatics;
Keywords
Longitudinal Data; Self-Controlled Case Series; Computa-
tional Drug Repositioning
1. INTRODUCTION
Drug repositioning is the task of identifying new potential
indications for existing drugs. This task has been steadily
rising to prominence because the traditional process of de
novo drug discovery can be slow, expensive, and risky [Ash-
burn and Thor, 2004]. Moreover, with the advent of the
big data era, abundant data sources that collect rich drug-
related information are emerging. Mining large-scale het-
erogeneous drug-related data sources, Computational Drug
Repositioning (CDR) has become an active research area
that has the potential to deliver more effective drug reposi-
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tioning. There have been several comprehensive reviews in
the literature on CDR [Hurle et al., 2013, Li et al., 2015].
Many methods leverage genotypic and transcriptomic infor-
mation [Lamb, 2007, Kuhn et al., 2010], as well as drug
molecular structure and drug combination information [Liu
et al., 2010, Knox et al., 2011]. A prior study that used
Electronic Health Records (EHRs) to validate a potential
indication of one existing drug has also been reported [Xu
et al., 2014].
We are interested in mining EHRs in order to identify a
potential indication from multiple existing drugs simultane-
ously. As an initial attempt, we examine the numeric values
of fasting blood glucose (FBG) level recorded in patients’
EHRs before and after some drugs are prescribed to those
patients, in the hope of identifying previously unknown po-
tential uses of drugs to control blood glucose level.
For this purpose, we extend the Self-Controlled Case Se-
ries (SCCS) [Simpson et al., 2013] model that has been
widely used in the Adverse Drug Reactions (ADRs) dis-
covery community to handle continuous numeric response,
hence the name of our model, Continuous Self-Controlled
Case Series (CSCCS).
The cornerstone of a self-controlled method is an under-
standing of how drug prescription history will potentially
influence the FBG level every time such a measurement is
taken. For example, an antibiotic drug taken ten years ago
might have less, if any, influence on the FBG level than
an anti-diabetic drug taken a day before that FBG level is
measured. To determine how long a drug can potentially
influence a patient, we furthermore propose a data-driven
approach that leverages change point detection [Muggeo,
2003], resulting in estimations of different time spans of in-
fluence for different drugs.
Our contributions are three-fold:
• To the best of our knowledge, this is the first translation of
SCCS methodology from ADR discovery to CDR. Our work
is a pilot study evaluating the use of temporal ordering in-
formation between numeric physical measurements and drug
prescriptions available in EHRs for the knowledge discovery
process of CDR.
• Based on the insightful observations of Xu et al. [2012], we
derive our CSCCS model from a fixed effect model and hence
extend the original SCCS model to address continuous nu-
meric response variables.
• We introduce to the CDR and ADR discovery community
a data-driven approach for adaptively determining the time
spans of influence of different drugs to the patients.
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Figure 1: An example of EHRs
2. CONTINUOUS SELF-CONTROLLEDCASE
SERIES (CSCCS) MODEL
2.1 Notation
Figure 1 visualizes an example of health records for two
patients. To confine the time span of a drug that has po-
tential influence on that patient, we use the concept of drug
era, which is recorded with its start date, end date and the
name (or id) of the drug. We consider a patient to be un-
der consistent influence of a drug during a drug era of that
drug. However, drug era information is not readily available
in most EHRs. Instead, drug prescription information with
the name of a drug and the start date of the prescription
is usually provided in observational data. How to construct
drug eras from prescription records is a challenging and sig-
nificant task for both CDR and ADR discovery [Nadkarni,
2010, Ryan, 2010]. We provide a data-driven approach to
this task in Section 4.
Measurements of FBG level might also be taken from time
to time and are recorded with the date taken, as well as their
numeric measurement values. We assume that at most one
FBG measurement is taken for a particular patient on a
particular day.
Let there be N patients with FBG measurements and M
different drugs in the EHR. We construct a cohort using
all the FBG measurement records as well as all the drug
era records from all the N patients. Furthermore, we use
a continuous random variable yij , where i ∈ {1, 2, · · · , N},
j ∈ {1, 2, · · · , Ji}, to denote the value of the jth FBG mea-
surement taken among a total number of Ji measurements
during the observation period of the ith person. Similarly, we
use a binary variable xijm, i ∈ {1, 2, · · · , N}, j ∈ {1, 2, · · · , Ji},
m ∈ {1, 2, · · · ,M} to denote the exposure status of the mth
drug of the ith person at the date when the jth FBG mea-
surement is taken, with 1 representing exposure and 0 oth-
erwise.
2.2 The Linear Fixed Effect Model
We treat the yij ’s as the response variables and first con-
sider the following linear regression model:
yij |xij = αi + β>xij + ij , ij iid∼ N
(
0, σ2
)
, (1)
where
β =
[
β1 β2 · · · βM
]>
, xij =
[
xij1 xij2 · · · xijM
]>
,
αi, which is called the nuisance parameter, represents the in-
dividual effect of the ith person on the value of yij , invariant
to day j, drug m, and other patients, and ij ’s are indepen-
dent and identically distributed Gaussian noises with zero
mean and fixed but unknown variance σ2.
The parameter of interest in this problem is β, which rep-
resents the effect of each of the M drugs on the response y
when a patient is under the joint exposure statuses specified
by xij . More specifically, suppose the m
th component of β,
βm, is evaluated to a negative number, that is to say, expo-
sure to the mth drug will cause the FBG level to decrease.
If this drug is not known to be prescribed for lowering FBG,
such a decrease is an indicator that this drug might have the
potential to be repositioned to help diabetic patients control
their blood glucose level, given further investigation.
In this setting, fitting a linear regression model is equiva-
lent to solving the following least squares problem:
arg minα,β
1
2
∥∥∥∥y − [Z X] [αβ
]∥∥∥∥2
2
, (2)
where
α =
[
α1 α2 · · · αN
]>
, Z = diag (11, · · · ,1N ) ,
y =
[
y11 · · · y1J1 · · · yN1 · · · yNJN
]>
,
X =
[
x11 · · · x1J1 · · · xN1 · · · xNJN
]>
,
where Z is a block diagonal matrix with 1i being a Ji × 1
vector where all the components are 1. The least squares
problem in (2) is a linear fixed effect model with α being
a nonrandom quantity whose ith component αi, can be in-
terpreted as the average FBG measurement level of the ith
patient taken over time without exposing to any drugs.
2.3 Deriving the CSCCS Model from the Lin-
ear Fixed Effect Model
Like the SCCS model, the motivation behind the CSCCS
model is to use only β as a parsimonious parameterization
to predict the response vector y. Inspired by the work in
[Xu et al., 2012], where the equivalence between the Poisson
fixed effect model and the SCCS model is established, we
are able to derive the CSCCS model from the linear fixed
effect model in (2) in a similar fashion. Let
` (α,β) =
1
2
∥∥∥∥y − [Z X] [αβ
]∥∥∥∥2
2
.
We consider,
∂` (α,β)
∂α
= 0⇒ α =
(
Z>Z
)−1
Z> (y −Xβ) = y¯ − X¯β,
(3)
where y¯ is an N × 1 vector with the ith component, y¯i =
1
Ji
∑Ji
j=1 yij , and X¯ is an N ×M matrix with the ith row,
X¯i· = 1Ji
∑Ji
j=1 x
>
ij . Substitute (3) into (2) results in the
CSCCS model:
arg minβ
1
2
‖y −Zy¯ − (X −ZX¯)β‖22. (4)
The model in (4) is in the desired form of parsimonious
parameterization in that the optimization problem is defined
only in the sapce of β, and the nuisance parameter α is
eliminated.
The CSCCS model is a linear model and hence CSCCS
is able to predict continuous response y. The model is self-
controlled in that each FBG measurement and their corre-
sponding drug exposure statuses are adjusted by their mean
within each individual. The model also utilizes case series
in that only cases (patients that have at least one FBG mea-
surement) are admitted in the cohort.
CSCCS is derived from its linear fixed effect model coun-
terpart. This derivation shares the same spirit with the
equivalence between the original SCCS and the Poisson fixed
effect model; in this sense, CSCCS extends SCCS to address
numeric response in the new setting.
Although both models in (2) and (4) can be considered
as linear models, from the perspective of implementation
efficiency, the explicit form of CSCCS in (4) is of vital im-
portance for the task of CDR using large-scale EHRs. This
is because the parameter of interest in our task is β and
the nuisance parameters do not provide direct information
in evaluating the impact of a drug in changing FBG level. In
the setting of large-scale EHRs, where tens of thousands of
patient records might be admitted into the cohort as cases,
the dimension of the nuisance parameter can potentially be
very high. In this scenario, without the access to a special
purpose solver for the fixed effect model, solving a model in
the form of (2) using only a general purpose linear model
solver can be time consuming or even infeasible. On the
contrary, using the explicit form of CSCCS in (4), a gen-
eral purpose linear model solver only needs to find solutions
in the space of β, a parameter whose dimension is only as
large as the number of drugs available in the cohort, which
is a much smaller number than the dimension of nuisance
parameters.
3. CHALLENGES IN EHR DATA
Several challenges arise when we apply CSCCS to EHR
data. In this section, we present the further refinements we
perform on the CSCCS model presented in (4) in order to
address these challenges.
3.1 High Dimensionality
EHR data is a type of high-dimensional longitudinal data.
While tens of thousands of patient records might be admit-
ted into the cohort, effects of thousands of drugs on the
FBG level need to be evaluated simultaneously, introducing
a high-dimensional problem. This motivates us to incorpo-
rate sparsity into our model using the penalty [Tibshirani,
1996],
arg minβ
1
2
‖y −Zy¯ − (X −ZX¯)β‖22 + λ‖β‖1, (5)
where λ > 0 is a tuning parameter determining the level of
sparsity.
The incorporation of this penalty essentially assumes that
only a small portion of drugs are related to the change of
FBG level, and the rest of them do not have significant effect
on changing FBG level when patients are exposed to those
drugs. With the L1 penalization, most components of β will
be evaluated to zero or a number that is close to zero. The
result is, instead of evaluating the effect of each of the M
drugs on FBG level, L1 penalized CSCCS only selects a sub-
set of drugs that, in some sense, are most correlated to the
change of FBG level, and estimates their relative strength
and direction of change among the drugs chosen.
3.2 Irregular Time Dependency
The linear fixed effect model assumes that all responses
are independent of each other. The meaning of independence
is two-fold. On one hand, responses from different patients
are independent of each other. To explain differences across
patients (e.g. some patients tend to have higher FBG lev-
els than others in general), α is used with each component
representing the time-invariant effect of each patient on the
response. On the other hand, responses observed at different
time are independent of each other. To explain differences
across time (e.g. FBG levels observed in early age might be
lower than those in old age), a time-dependent variable that
has the same value across all patients can be introduced.
That is to say:
yij |xij = αi + tj + β>xij + ij , (6)
where tj is the time-dependent nuisance parameter whose
value depends only on the time when the jth measurement
is taken. If observations are recorded regularly across time,
(6) defines a two-way fixed effect model, as opposed to the
one-way fixed effect model defined in (2) [Frees, 2004].
In practice, a one-way model might be preferred over a
two-way model if we assume that the heterogeneity across
different individuals is much more significant than that across
time. However, in the task of CDR from EHRs, this assump-
tion might be too restrictive. To begin with, EHRs usually
contain observational data of patients that are recorded over
decades. Therefore, it is probable that the baseline FBG
levels of patients change significantly over the years. This
is especially true when some persistent FBG level altering
events, such as the diagnosis of diabetes, occur to some pa-
tients. Furthermore, the length of observation periods varies
dramatically among patients. Therefore, we do not have a
fully observed and consistent dataset to model the set of
time-dependent nuisance parameters. Last but not least, the
incorporation of time-dependent nuisance parameters is pro-
posed in a setting where data are collected regularly. With
the irregular nature of EHR data, modeling time-dependent
nuisance parameters directly with a classic two-way fixed
effect model is impractical.
To address the aforementioned challenges without much
loss in efficiency, we consider a reasonable assumption: given
yij and yij′ , where j 6= j′, but the dates of the two measure-
ments taken are very close to each other, we assume the
two corresponding time-dependent nuisance parameters are
equal to each other, i.e. tj = tj′ . More specifically,
yij |xij = αi + tj + β>xij + ij ,
yij′ |xij′ = αi + tj′ + β>xij′ + ij′ ,
|dij − dij′ | ≤ τ ⇒ tj = tj′ ,
where dij and dij′ represent that the j
th and j′th measure-
ments of the ith patient are taken at the dthij day and d
th
ij′ day
of the observation period, and τ is a predetermined thresh-
old. Then,
E [yij − yij′ |xij ,xij′ ] = β> (xij − xij′) ≡ β>δij , (7)
where the nuisance parameters are eliminated. Therefore,
the quantity in (7) depends only on β and the data.
Based on this formulation, we can reconstruct the CSCCS
model to address irregular time dependency as follow: firstly,
given τ , construct a cohort where only patients with at least
a pair of FBG measurements taken within τ days are ad-
mitted; only adjacent pairs are used. Secondly, solve the
following lasso problem:
arg minβ
1
2
‖Dy −DXβ‖22 + λ‖β‖1, (8)
where D, when multiplied with y or X, generates the differ-
ence between the measurement of an earlier record and the
corresponding measurement of its adjacent later-measured
record of the same patient, with the constraint that the two
records are collected within a time span of τ days.
Note that the model in (8) is not equivalent to the model
in (5). However, the model in (8) can still be considered
as a variant of CSCCS in that its parameterization is still
restricted to β, with the goal of predicting a continuous
response, using data subtraction within the same patient as
a self-controlled mechanism, and only admitting cases into
the cohort. We call the the model in (8) as CSCCS for
Adjacent response, or CSCCSA.
3.3 Confounding
Another challenge an algorithm must tackle is the con-
founding issue arises due to the complex nature of clinical
observational data. In the setting of EHRs, one important
confounding issue is called confounding by co-medication.
Consider drug A and drug B, where only drug A can lower
FBG level and drug B has no significant effect on changing
blood sugar. However, drug B is usually prescribed with
drug A. In this case, drug B can be a confounder if we only
evaluate the marginal correlation between each drug and
FBG level. Another confounding issue in this setting is con-
founding by comorbidity. Consider the FBG-lowering drug
A given to a diabetic patient. Following the prescription of
drug A, some other conditions could occur to this patient
since diabetes can lead to various comorbidities [AACE]. To
treat a newly introduced condition, drug B is prescribed
to the patient. In this case, if we again consider only the
marginal correlation between drug B and FBG level, one
might draw the conclusion that drug B could lower FBG
level since after the prescription of drug A, the FBG level
has decreased.
In the two aforementioned confounding issues, drug B is
called an innocent bystander. Like multiple SCCS [Simp-
son et al., 2013], multiple CSCCS can effectively handle the
innocent bystander confounding problem (a.k.a. Simpson’s
Paradox). This is because the confounder seems to spu-
riously correlated to the FBG level when we consider their
marginal correlation. However, using a multiple linear model
like CSCCS, the joint exposure statuses of both drug A and
drug B can be considered simultaneously. Thereofre, CSCCS
might be able to identify that the decrease of FBG level oc-
curs only when conditioning on the exposure of drug A and
hence rule out drug B in the model.
In terms of addressing various confounding issues, CSCCS
inherits most of the strengths and weaknesses from SCCS,
due to the close relationship between the two models. While
CSCCS might address reasonably well the innocent bystander
confounding problem, it might not be well suited to handle
confounding issues such as time-varying confounding [Daniel
et al., 2013]. In Section 5, we empirically evaluate the per-
formance of CSCCS in the CDR task and illustrate how its
performance is related to its capabilities of addressing vari-
ous confounding issues.
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Figure 2: Time gap of humalog in asecneding order: the size
of dots represents the number of time gaps that share the
same value
4. A DATA-DRIVEN APPROACH TO CON-
STRUCTDRUGERAS FROMDRUGPRE-
SCRIPTION RECORDS
A prerequisite of CSCCS is the availability of drug era in-
formation of each drug prescribed to each patient. However,
drug era information is usually not provided in most EHRs.
Instead, drug prescription records of each patient are kept,
usually with the name (or id) of the drug and the date of
prescription. Constructing drug eras from drug prescription
records is an important but challenging task for both CDR
using CSCCS and ADR discovery.
4.1 Drug Era in Common Data Model
A heuristic proposed in the Common Data Model (CDM)
[Reisinger et al., 2010] by Observational Medical Outcome
Partnership (OMOP) is to first consider the prescription
dates of each prescription record as the start date of the
drug era. It then assumes that each drug era lasts n days
and hence computes the end date of the drug era accord-
ingly. Within the same patient, we assume there is only one
drug prescription record of the same drug in a given date.
In this way, drug eras of the same drug within each patient
constructed as before start from different dates. For an ad-
jacent pair of drug eras of the same drug within the same
patient, we call the drug era that starts earlier a former era,
and the other a latter era. CDM defines a parameter called
persistence window. If the start date of the latter era, sub-
tracted by the end date of the former era, is no larger than
the persistence window, CDM merges the two drug eras into
one, using the start date of the former era as the start date
of the new era and the end date of the latter era as the end
date of the new era. CDM tries to merge as many drug
eras of the same drug within the same patient as possible in
this fashion, until every resultant drug era of the same drug
within the same patient is separated by more than persis-
tence window amount of time. In CDM, both n and the
persistence window are usually set to thirty days.
The intuition behind this heuristic is to build a longer drug
era if the prescription date of an adjacent pair of records of
the same drug are close enough to each other. A natural
question to ask is how large the time gap between the two
adjacent prescription records can be for us to still consider
them close enough?
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4.2 Drug Era Construction via Change Point
Analysis
Instead of specifying a predetermined threshold on time
gap as it is in CDM, we answer this question via a data-
driven approach: for each drug, we compute the time gaps
between all adjacent pairs of prescription records. We then
sort these time gaps in ascending order. A visualization of
the values of the time gaps of Humalog against their rela-
tive rankings is given in Figure 2. From Figure 2, we notice
that the distribution of time gaps can be approximated by
a piecewise linear model with a change point close to the
end of the sample with large time gap values. The smaller
time gaps can be fitted well by the flat linear segment of the
model while the larger time gaps can be fitted well by the
steep linear segment. This phenomenon leads to a reason-
able assumption that the smaller time gaps are sampling
from a different underlying distribution than that of the
larger time gaps. The smaller time gaps sampling from the
same distribution correspond to the adjacent pairs of pre-
scription records that we can consider close enough to each
other to construct a lasting drug era. A threshold we can
use to distinguish the two types of time gaps is the change
point of the piecewise linear model.
For each drug with at least fifty prescription records in
the EHRs, we perform change point detection analysis in
the aforementioned fashion using R package segmented. We
plot the change points of all the drugs against their relative
rankings after sorting them in ascending order in Figure 3.
Interestingly, there is also a change point in Figure 3. A
possible explanation of the existence of a change point in
Figure 3 is that in EHR data, drug prescriptions of some
particular drugs are recurrent in order to battle chronic dis-
ease. For example, a diabetic patient needs long-term pre-
scriptions of some FBG lowering drugs. On the other hand,
the prescriptions of some other drugs are non-recurrent, such
as antibiotics. We consider the change point in Figure 3 as a
threshold to distinguish recurrent drugs from non-recurrent
drugs in the EHR because a reasonable expectation is that
if a drug is recurrent, the gap between an adjacent pair of
prescription records of that drug from the same patient will
tend not to be too large and hopefully under the change
point specified in Figure 3.
We extend the heuristic provided in CDM as follow: We
first denote the mean of all change point values of the recur-
rent drugs in the EHR as γ. For all the recurrent drugs, we
set their corresponding n’s and the value of their persistence
windows to γ
2
. We then set n = 0.04year (approximately two
weeks) for all non-recurrent drugs and 0 as the value of their
persistence windows.
5. EXPERIMENTS
As far as we know, our CSCCS model is the first of its kind
to explicitly use temporal ordering information in EHRs for
CDR. How do we evaluate the performance of a method
that utilizes this type of information? As a preliminary en-
deavor, we try to answer this question by addressing two
major challenges for our experiments.
5.1 Lack of a Baseline Method
The first challenge we need to handle is the lack of a base-
line method that also utilizes temporal ordering information
in an EHR for CDR. Inspired by the idea of disproportion-
ality analysis from the pharmacovigilance literature [Mon-
tastruc et al., 2011], we propose the Pairwise Mean (PM)
method as a baseline method. PM assigns a real-valued score
to each of the M drugs in the EHR to represent how likely
the drug decreases FBG level, and a smaller score implies
a stronger decreasing tendency. The score of the mth drug,
sm, is computed as follow: first, for the i
th patient who has
FBG measurements within two years before and after the
first prescription of the mth drug, we compute the mean of
those FBG measurements before and after the first prescrip-
tion, denoted as bmi and ami, respectively; second, compute
sm as:
sm =
1
Nm
Nm∑
i=1
(ami − bmi) ,
where Nm is the number of patients that have FBG mea-
surements two years before and after the first prescription
of the mth drug.
5.2 Incomplete Ground Truth
Unlike the task of ADR discovery from the EHR, where
numerous research efforts have been invested on developing
a set of ground truth [OMOP, 2015] drug-adverse-reaction
pairs so that algorithms can be run and evaluated, we do
not have access to such a ground truth set for the task of
CDR from EHRs. We use Marshfield Clinic EHR as our
data source and there are about two thousand drugs for
evaluation. To evaluate the performance of our algorithm
without knowing the glucose altering effect of every drug,
we focus on the top forty most promising drugs generated
by PM, CSCCS, and CSCCSA, as shown in Table 2, Table 3,
and Table 4, respectively.
In these three tables, rows that are shaded in green rep-
resent the drugs commonly prescribed for lowering glucose
while rows that are shaded in red represent the drugs com-
monly prescribed for increasing glucose. The two types of
drugs in the three tables are all manually labeled. Drugs in
the unshaded rows might potentially be irrelevant, or might
constitute new discoveries. These drugs are discussed in fur-
ther detail in Section 5.6. A summary of the number of each
of the three types of drugs discovered by the three algorithms
are given in Table 1.
In CSCCSA, we set τ defined in Section 3.2 to four years.
In Table 2, the counts and scores are Nm’s and sm’s defined
in Section 5.1, while in Table 3 and Table 4, the counts are
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Figure 4: ROC curves
the L1 norm of the columns in X corresponding to different
drugs, and the scores are the regression coefficients of differ-
ent drugs. We only consider drugs with counts greater than
or equal to eight. For CSCCS and CSCCSA, we first used
a lasso penalty for variable selection to generate a long list
of about two hundred drugs, and we present the top forty
among those selected drugs as the short list. The num-
ber eight and forty could be tuned to optimize accuracy but
were fixed here beforehand for practical reasons. Drugs with
fewer than eight prescriptions might not have sufficient ev-
idence to support a new use. Evaluating more than forty
results per method was too large a burden for human liter-
ature review.
Table 1: A summary of three types of drugs discovered by
the three algorithms
PM CSCCS CSCCSA
decrease 15 16 27
increase 1 1 0
potential 24 23 13
5.3 Receiver Operating Characteristic
As shown in Tables 2–4, all three methods capture a rea-
sonable number of drugs that are prescribed for lowering
glucose among their top forty candidates. We therefore con-
sider identifying drugs prescribed for glucose-lowering as a
binary classification task and use Receiver Operating Char-
acteristics (ROC) curves as well as Area Under ROC (AU-
ROC) to evaluate the performance of each algorithm.
We first construct the ROC curves of the three methods
using the union list of drugs from Tables 2–4. The three
ROC curves are presented in Figure 4(a). Since we per-
form variable selection in CSCCS and CSCCSA, some drugs
might be assigned scores of zero and hence are considered
irrelevant to the prediction of FBG level. In these cases, we
put these drugs at the bottom of the union list and consider
them to be identified as positive examples by the algorithms
only at the very end. This results in the straight line segment
of the ROC curves of CSCCS and CSCCSA at the liberal
region. Figure 4(a) shows that CSCCSA has the highest
AUC, outperforming CSCCS and PM by a significant mar-
gin, while PM and CSCCS have similar AUCs. However, in
the more conservative region where there is drug support for
all three methods, CSCCS outperforms PM while CSCCSA
maintains the best performance. This phenomenon suggests
that the modeling assumptions of CSCCS and CSCCSA are
able to provide insights into making reasonable prediction
of FBG level.
Figure 4(b) uses the forty drugs in Tables 2 and 3 to gen-
erate the ROC curves, in red for PM and in blue for CSCCS.
As a comparison, we also plot the ROC curve of the following
ensemble strategy: we first use the top forty drugs in Table 3
as a result of variable selection via CSCCS, then we com-
pute the PM scores over the selected drugs. By comparing
the AUCs of the three curves, we notice that the ensemble
method outperforms CSCCS and PM, while CSCCS outper-
forms PM. Since the scores used to construct the CSCCS
ROC curve are regression coefficients of drug exposure sta-
tuses under a lasso penalty, the lack of an oracle property
for the lasso [Wainwright, 2009] might potentially trade off
the inherent order among drugs for a sparse model. How-
ever, such a trade-off is beneficial, based on the significant
improvement of AUC of CSCCS compared with the AUC of
PM.
Figure 4(c) is generated similarly as Figure 4(b). The en-
semble of CSCCSA with PM outperforms the two individual
algorithms. Although the AUC of CSCCSA is less than that
of CSCCS, it is worthy to notice that all but one true pos-
itive drugs in Table 3 are discovered in Table 4 at the top
fifteen positions. Other than that, CSCCSA is also able to
discover twelve more true positives that CSCCS does not
capture among its top forty discoveries.
5.4 Precision at K
The task of CDR from EHRs is somewhat analogous to
web search. Specifically, the algorithm should select only
a few drugs that have interesting unexpected effects on the
response: returning too many results makes it infeasible for
human experts to evaluate the potential effect of the selected
drugs. This is similar to users performing web search on a
search engine, where typically only the quality of the results
on the first page, or the first K results, matters. Based on
this observation, an algorithm with a high precision-at-K
value is desirable. Figure 5 shows the precision of each of
the three algorithms at different positions (K) in the task of
identifying drugs prescribed for lowering glucose. CSCCSA
achieves the highest performance at all positions. CSCCS
outperforms PM significantly at smaller K’s, but the perfor-
mances of the two algorithms are similar at larger K’s. This
is consistent with results in Table 1, showing that CSCCSA
is able to identify more prescribed drugs for lowering glucose
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Figure 5: Precision at K of PM, CSCCS, and CSCCSA
than the other two methods. Moreover, these drugs are at
the very top of Table 4. Therefore, precision-at-K provides
evidence for CSCCSA’s utility for CDR from EHRs.
5.5 Drugs with KnownGlucose Increasing/ De-
creasing Effects
From Tables 2–4, we notice that CSCCSA discovers the
most number of drugs prescribed for lowering glucose among
the three methods under consideration. This reaffirms our
belief that CSCCSA is a promising method for CDR from
EHR. Furthermore, we also notice that drugs prescribed
for increasing glucose are reported in all but the table of
CSCCSA.
In Table 2, sucrose is observed as a false positive using
PM. Based on its count, this might be a spurious correlation
in the data. This is even more probable when we consider
the fact that the effect of sucrose on blood glucose level
is short-term, and sucrose is not a drug that consistently
enter patients’ EHR for a long period of time. However, PM
considers the glucose measurement records of the patients
within two years before and after the first prescription of
sucrose, during which many stronger confounding factors
could have occurred to alter the glucose level.
In Table 3, glucagon is identified. Glucagon is given to
diabetic patients that take glucose-lowering drugs to avoid
hypoglycemia. However, glucagon alone is not frequently
administered. Therefore, in the data, we observe the co-
occurrence of glucagon with various glucose-lowering drugs.
While glucagon alone increase blood glucose, combining with
glucose-lowering drugs usually results in the decrease of blood
sugar. On the other hand, we did not have enough data
where glucagon is prescribed alone to observe the responses.
Therefore, the algorithm will consider glucagon to have glucose-
lowering effects since most of the time the occurrence of
glucagon is accompanied by blood sugar decreasing medi-
cations. The algorithm might even consider it as a strong
glucose-lowering drug because the actual glucose-lowering
drugs are coded in various names in the EHR, hence dis-
persing the effect, while glucagon is coded only by a few
different names.
5.6 Confounding and Potential Drugs
We now turn to the discussion of the drugs discovered by
the three algorithms in Table 2–4 that are not prescribed
for glucose increasing/decreasing. We will make use of a
list providing drugs that can influence blood glucose level
available in [DiabetesInControl, 2015] to aid our evaluation
process.
5.6.1 The Blessing and the Curse of Marginal Cor-
relations
According to [DiabetesInControl, 2015], in Table 2, Acti-
gall can cause blood glucose level to increase while ampho-
tericin B can cause blood glucose level to decrease. An in-
teresting drug that is also brought to our attention is buder-
prion SR. Buderprion SR is an antidepressant prescribed for
the treatment of depressive disorder. For diabetic patients
with depression, buderprion SR can help to alleviate their
depressive symptom, making them in a better mood. This
in turn has a positive effect on better controlling blood glu-
cose level for longer period of time [Lustman et al., 2007].
PM is able to discover the blood glucose lowering effect
of buderprion SR, even with a mere support of nine pa-
tients. The fact that PM considers the marginal correlation
of each drug-indication pair independently makes it more
likely to discover interesting drug-indication pairs with a
weaker support. However, spurious correlations, especially
those caused by the innocent bystander problem, are also
more likely to be reported this way.
Comparing the results from Table 2 with those from Ta-
ble 3 and Table 4 could justify our argument. In Table 2,
Habitrol is a nicotine patch, and Monistat, Voriconazole,
amphotericin B, and Hibiclens are all used to treat fungal
infection. Interestingly, fungal infection is a comorbidity of
diabetes [Vazquez and Sobel, 1995, ADA], and smokers are
also more inclined to be diabetic [CDC]. On the other hand,
we cannot find any drugs that are related to fungal infection
or quitting smoke in Table 3 and Table 4. This comparison
suggests that the aforementioned drugs in Table 2 gener-
ated by marginal association methods like PM might be in-
nocent bystanders while a multiple regression approach such
as CSCCS and CSCCSA might significantly help to alleviate
this type of confounding issue.
5.6.2 Potential drugs found by CSCCS and CSCCSA
In Table 3, a study [Vermes et al., 2003] indicates that
enalapril helps to decrease the occurrence rate of diabetes
in patients with chronic heart failure. Tricor might also
have the potential to lower blood sugar level, based on the
findings in Damci et al. [2003] and Balakumar et al. [2014].
Vitamin B12 is another interesting drug for consideration.
In a rat model used by Chow and Stone [1957], deficiency in
vitamin B12 is linked to hyperglycemia. However, blood glu-
cose level can be decreased by providing vitamin B12. A re-
cent study suggests that diabetic patients under metformin
might experience vitamin B12 deficiency [Ting et al., 2006].
In a study on depressive patients, Zoloft, which is an antide-
pressant, is linked to the increase of insulin level after its
prescription [Kesim et al., 2011]. Zestril, which is the brand
name of lisinopril, is found to inhibit high blood sugar level
in rats [Balakumar et al., 2014]. Captopril is also reported to
improve daily glucose profile among non-insulin-dependent
patients [Kodama et al., 1990]. However, hydralazine HCl
is linked to glucose-increasing in a rat model, according to
the findings in Satoh et al. [1980]. Nifedipine, verapamil
HCl, and morphine sulfate can decrease blood sugar while
Table 2: Top forty drugs: PM-Glucose
INDX CODE DRUG NAME SCORE COUNT
1 5226 LANTUS -41.672 34
2 6646 NOVOFINE 31 -38.709 33
3 5789 METFORMIN HYDROCHLORIDE -38.623 10
4 5806 METHENAM/MBLU/BA/SAL/ATROP/HYO -36.710 10
5 4811 INSULIN NPH -34.573 23
6 6652 NOVOLOG -29.895 54
7 4336 HABITROL -29.871 16
8 6044 MONISTAT -29.721 14
9 9080 SURFAK -29.655 14
10 9155 SYRNG W-NDL DISP INSUL 0.333ML -29.439 30
11 4500 HUMULIN -29.186 36
12 9008 SUGAR SUBSTITUTE -28.971 10
13 10176 VORICONAZOLE -28.538 10
14 1305 BUDEPRION SR -27.444 9
15 8450 ROXICODONE -27.428 12
16 9534 TRANDATE -25.978 8
17 4802 INSULIN -24.507 697
18 3849 FLURBIPROFEN SODIUM -24.403 11
19 8316 REZULIN -24.287 135
20 5257 LENALIDOMIDE -22.875 8
21 4485 HUMALOG -22.852 67
22 1389 CAL -22.817 61
23 144 ACTIGALL -22.237 36
24 8998 SUCROSE -22.125 18
25 3843 FLUPHENAZINE HCL -22.094 8
26 3682 FERROUS FUMARATE -21.225 10
27 9104 SYMLINPEN 120 -20.333 12
28 1868 CHLORAMBUCIL -20.268 14
29 4171 GLUCOTROL XL -19.719 828
30 504 AMPHOTERICIN B -19.672 24
31 3778 FLEXOR -19.287 14
32 8241 REGULAR INSULIN -19.205 39
33 824 AVANDIA -19.140 487
34 5783 METAPROTERENOL -18.920 10
35 4434 HIBICLENS -18.863 10
36 5815 METH/ME BLUE/BA/PHENY/ATP/HYOS -18.727 11
37 5010 JANUVIA -18.716 11
38 4813 INSULIN NPL/INSULIN LISPRO -18.515 126
39 4595 HYDROMORPHONE -18.470 17
40 7626 POLYMYXIN B SULFATE MICRONIZED -18.456 11
Table 3: Top forty drugs: CSCCS-Glucose
INDX CODE DRUG NAME SCORE COUNT
1 7470 PIOGLITAZONE HCL -13.502 3075
2 8437 ROSIGLITAZONE MALEATE -13.465 1019
3 6656 NPH HUMAN INSULIN ISOPHANE -10.963 2874
4 4497 HUM INSULIN NPH/REG INSULIN HM -10.869 1829
5 160 ACTOS -7.665 1125
6 824 AVANDIA -7.543 1239
7 4837 INSULN ASP PRT/INSULIN ASPART -7.067 258
8 4806 INSULIN GLARGINE HUM.REC.ANLOG -5.571 4213
9 9152 SYRING W-NDL DISP INSUL 0.5ML -5.301 4186
10 8316 REZULIN -3.611 444
11 3227 ENALAPRIL -3.218 1103
12 6382 NEEDLES INSULIN DISPOSABLE -3.148 2827
13 4970 ISOSORBIDE DINITRATE -3.122 1220
14 9623 TRICOR -3.119 821
15 3686 FERROUS SULFATE -2.898 4820
16 1760 CELEXA -2.887 1473
17 4802 INSULIN -2.806 1526
18 4118 GLUCAGON HUMAN RECOMBINANT -2.722 1639
19 5786 METFORMIN -2.625 3838
20 7731 PRAVACHOL -2.458 1700
21 2512 DARBEPOETIN ALFA IN ALBUMN SOL -2.359 426
22 6210 MYCOPHENOLATE MOFETIL -2.253 724
23 2830 DILTIAZEM -2.216 1021
24 5636 MAVIK -2.150 2242
25 4132 GLUCOPHAGE -2.133 6736
26 4525 HYDRALAZINE HCL -2.095 792
27 4106 GLIMEPIRIDE -2.034 3384
28 7129 PAXIL -2.033 2021
29 2426 CYANOCOBALAMIN (VITAMIN B-12) -1.992 4080
30 4833 INSULIN ZINC HUMAN REC -1.945 116
31 10392 ZOLOFT -1.926 2417
32 6069 MORPHINE SULFATE -1.889 899
33 10333 ZESTRIL -1.787 2032
34 1216 BLOOD SUGAR DIAGNOSTIC -1.665 19832
35 10199 WARFARIN SODIUM -1.632 9223
36 3937 FOSINOPRIL SODIUM -1.540 2660
37 6499 NIFEDIPINE -1.524 1472
38 1003 BENAZEPRIL HCL -1.462 1586
39 9994 VERAPAMIL HCL -1.433 1856
40 1573 CAPTOPRIL -1.418 1989
Table 4: Top forty drugs: CSCCSA-Glucose
INDX CODE DRUG NAME SCORE COUNT
1 4485 HUMALOG -11.786 124
2 7470 PIOGLITAZONE HCL -10.220 3075
3 8437 ROSIGLITAZONE MALEATE -9.731 1019
4 4837 INSULN ASP PRT/INSULIN ASPART -9.658 258
5 6382 NEEDLES INSULIN DISPOSABLE -9.464 2827
6 4171 GLUCOTROL XL -8.117 2853
7 4106 GLIMEPIRIDE -7.940 3384
8 160 ACTOS -7.721 1125
9 824 AVANDIA -6.802 1239
10 9152 SYRING W-NDL DISP INSUL 0.5ML -6.623 4186
11 4132 GLUCOPHAGE -6.322 6736
12 4184 GLYBURIDE -6.021 8879
13 4170 GLUCOTROL -5.721 1259
14 4208 GLYNASE -5.670 591
15 416 AMARYL -5.599 2240
16 4107 GLIPIZIDE -5.563 9993
17 844 AXID -4.682 189
18 2830 DILTIAZEM -4.297 1021
19 4806 INSULIN GLARGINE HUM.REC.ANLOG -4.175 4213
20 5787 METFORMIN HCL -4.147 19584
21 2824 DILAUDID -4.076 39
22 5786 METFORMIN -3.890 3838
23 7731 PRAVACHOL -3.532 1700
24 1760 CELEXA -3.517 1473
25 4497 HUM INSULIN NPH/REG INSULIN HM -3.501 1829
26 9889 URSODIOL -3.132 376
27 4813 INSULIN NPL/INSULIN LISPRO -2.972 623
28 4133 GLUCOPHAGE XR -2.845 765
29 6445 NEURONTIN -2.615 1418
30 6656 NPH HUMAN INSULIN ISOPHANE -2.500 2874
31 9379 THIAMINE HCL -2.383 341
32 1636 CARDURA -2.198 1079
33 1218 BLOOD SUGAR DIAGNOSTIC DRUM -2.073 2593
34 8025 PROZAC -2.037 1525
35 8316 REZULIN -1.895 444
36 9136 SYRINGE & NEEDLE INSULIN 1 ML -1.885 3542
37 4802 INSULIN -1.812 1526
38 7674 POTASSIUM CHLORIDE -1.779 9842
39 4804 INSULIN ASPART -1.752 2476
40 1200 BLOOD-GLUCOSE METER -1.719 5289
Table 5: Top forty drugs: CSCCSA-LDL
INDX CODE DRUG NAME SCORE COUNT
1 8444 ROSUVASTATIN CALCIUM -17.052 27122
2 5368 LIPITOR -16.908 118468
3 2395 CRESTOR -16.234 3535
4 8720 SIMVASTATIN -15.790 206064
5 3584 EZETIMIBE/SIMVASTATIN -14.721 19396
6 790 ATORVASTATIN CALCIUM -13.982 151106
7 941 BAYCOL -12.924 1236
8 10383 ZOCOR -11.451 26514
9 10186 VYTORIN -9.877 9047
10 5487 LOVASTATIN -9.238 45286
11 3583 EZETIMIBE -8.093 32595
12 7731 PRAVACHOL -6.729 16525
13 10336 ZETIA -6.678 6623
14 7733 PRAVASTATIN SODIUM -6.638 33708
15 5261 LESCOL XL -6.358 873
16 9183 TAMOXIFEN CITRATE -4.777 3095
17 5893 MEVACOR -4.172 4205
18 2175 COLACE -4.016 4349
19 9182 TAMOXIFEN -3.764 2048
20 5260 LESCOL -3.716 6251
21 475 AMLODIPINE/ATORVASTATIN -2.779 1272
22 494 AMOXICILLIN/POTASSIUM CLAV -2.495 4186
23 2110 CLOPIDOGREL BISULFATE -2.271 50059
24 4616 HYDROXYCHLOROQUINE SULFATE -2.240 5888
25 5281 LEVAQUIN -2.194 1464
26 3471 ESTROGEN CON/M-PROGEST ACET -1.929 5896
27 7496 PLAVIX -1.471 14220
28 8225 RED YEAST RICE -1.345 5468
29 3746 FLAGYL -1.169 278
30 6540 NITROGLYCERIN -1.103 94747
31 2959 DOCUSATE SODIUM -1.084 32872
32 3475 ESTROGENS CONJUGATED -1.033 22480
33 3686 FERROUS SULFATE -0.990 32496
34 7768 PREMARIN -0.969 5513
35 865 AZITHROMYCIN -0.959 9861
36 2811 DIGOXIN -0.908 31353
37 4132 GLUCOPHAGE -0.779 14764
38 493 AMOXICILLIN -0.715 11214
39 1985 CIPROFLOXACIN -0.651 989
40 9946 VARENICLINE TARTRATE -0.636 10794
captopril interacting with hydrochlorothiazide could cause
high blood sugar, according to the list in DiabetesInControl
[2015]. The potential glucose-lowering drugs discovered in-
dicate that CSCCS is a reasonable method for the task of
CDR.
In Table 4, Pravachol is a member of a popular class of
drugs called statins which are prescribed to lower cholesterol
level. Although the Food and Drug Administration (FDA)
has added blood-glucose-increase warnings to all the drugs
in the statin class [FDA, 2014], Pravachol itself has been
considered to have blood-glucose lowering effects [Freeman
et al., 2001, Carter et al., 2013]. The fact that CSCCSA
can single out this particular drug from other statin class
drug members indicates the potential of the algorithm to
distinguish among similar drugs that have subtle differences.
Celexa has a mild but non-significant effect on FBG level re-
duction in a study with seventeen depressive patients [Ams-
terdam et al., 2006]. Several cases of hypoglycemia linked to
the use of Neurontin have also been reported [Scholl et al.,
2015]. Thiamine is reported to reduce the adverse effect
of hyperglycemia by inhibiting certain biological pathways
[vinh quoc Luong and Nguyen, 2012] and deficiency of thi-
amine is observed in diabetic patients [Page et al., 2011].
Cardura is found to reduce insulin resilience in a study on
hypertensive patients with diabetes [Inukai et al., 2004]. Ac-
cording to DiabetesInControl [2015], Prozac can cause both
high or lower blood sugar while diltiazem is linked to low
blood glucose level.
5.7 Experiments on Low-density Lipoprotein
To demonstrate the potential of our methodology, we also
apply our method to predict the numeric value of low-density
lipoprotein (LDL). We first construct drug eras from drug
prescription records with the approach proposed in Section 4.
We then run CSCCSA and generate a long list of about two
hundred drugs. We report the top forty drugs from the
list in Table 5. No confirmed false positives are discovered
in the table while all the confirmed true positives are re-
ported at the very top of the list. Some entries of hormone
are discovered, which are linked to the decrease of LDL in
drug/laboratory tests [FDA]. Interestingly, many entries of
antibiotics are discovered, and all of them are classified as
non-recurrent drugs by the algorithm in Section 4. This
is consistent with the clinical practice that antibiotics are
usually not prescribed for long-term use. Some antibiotics
have also been considered to manage cholesterol level, with
literature support dating back to the 1950’s [Samuel, 1979,
Kesa¨niemi and Grundy, 1984, Jenkins et al., 2005]. The ex-
perimental results on LDL suggest that our algorithm is not
fine-tuned to boost the performance on discovering drugs
that control FBG level. Instead, it is readily applicable to
other important numeric clinical measurements that might
lead to interesting discoveries in drug repositioning.
6. DISCUSSION
We have introduced the CSCCS model for the task of
CDR using EHRs. To our best knowledge, the proposed
model is the first of its kind to extensively leverage tempo-
ral ordering information from EHR to predict indications for
multiple drugs at the same time. The CSCCS model extends
the SCCS model that is popular in the ADR community to
address a continuous response. As an initial effort, we eval-
uate our methodology on the task of discovering potential
blood-sugar-lowering indications for a variety of drugs in a
real world EHR. We develop a set of experimental evalua-
tion methods specific to this problem in order to estimate
the performance of our method. Our experimental results
suggest that CSCCS can not only discover existing indica-
tions but is also able to identify potentially new use of drugs.
We hence believe that CSCCS is a promising model to aid
the knowledge discovery process in CDR.
Future applications and extensions of the CSCCS model
are exciting. To begin with, CSCCS can be applied to
a broad variety of numeric responses such as blood pres-
sure level, cholesterol level, or body weight, to name a few.
Therefore, potentially new indications of drugs to control
the aforementioned important physical measurements can be
examined in the same paradigm. Furthermore, many other
sources of patient information, such as demographic infor-
mation, diagnosis codes, other type of lab measurements,
as well as interactions among all these information sources
can be taken into consideration to facilitate the prediction
of the physical measurement level. Last but not least, al-
though the proposed CSCCS model in its simpliest form
is a linear model, the history of SCCS model development
[Madigan et al., 2015] could help guide on future develop-
ment of CSCCS model. More complicated models can be
derived from its simpler counterparts for better predictive
performance in more specific and refined applications.
We can learn a lot of lessons from the task of ADR dis-
covery from EHRs to perform the task of CDR from EHRs.
For one thing, a ground truth set for CDR algorithm eval-
uation using EHRs is desired and calls for multidisciplinary
collaborations from experts with different specialties. Fur-
thermore, the popularity of disproportionality analysis and
self-controlled methods in the ADR discovery community
suggestes the utility of analogous methods for CDR.
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